Genmab A/S and its wholly owned subsidiary Genmab Finance LLC have priced an offering of $1.5 billion in 6.250% senior secured notes due 2032 and $1.0 billion in 7.250% senior unsecured notes due 2033, with an issue price of 100%. The company has also completed the syndication of a new $2.0 billion senior secured term loan "B" facility, in addition to previously syndicated $1.0 billion senior secured term loan "A" facility and a $500 million senior secured revolving credit facility. Genmab intends to use the net proceeds from the new notes, the credit facilities, and cash on hand to fund the acquisition of Merus N.V., as well as related fees and expenses. The offering is expected to close on December 3, 2025, subject to customary closing conditions.